Multiple system atrophy: an update

The Lancet Neurology

Volumn 8, Issue 12, 2009, Pages 1172-1178

  Stefanova, Nadia ^a   Bücke, Philipp ^a   Duerr, Susanne ^a   Wenning, Gregor Karl ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; MINOCYCLINE; RASAGILINE; RIFAMPICIN; RILUZOLE;

BRAIN TRANSPLANTATION; CLINICAL FEATURE; CLINICAL TRIAL; GENETIC DISORDER; HUMAN; LEPROSY; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; REVIEW; SHY DRAGER SYNDROME; TUBERCULOSIS;

ALPHA-SYNUCLEIN; EXCITATORY AMINO ACID ANTAGONISTS; HUMANS; MULTIPLE SYSTEM ATROPHY; PROGNOSIS; RILUZOLE;

EID: 71849092562     PISSN: 14744422     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1474-4422(09)70288-1     Document Type: Review

References (65)

1. Graham J.G., and Oppenheimer D.R. Orthostatic hypotension and nicotine sensitivity in a case of multiple system atrophy. J Neurol Neurosurg Psychiatry 32 (1969) 28-34
2. Papp M.I., Kahn J.E., and Lantos P.L. Glial cytoplasmic inclusions in the CNS of patients with multiple system atrophy (striatonigral degeneration, olivopontocerebellar atrophy and Shy-Drager syndrome). J Neurol Sci 94 (1989) 79-100
3. Spillantini M.G., Crowther R.A., Jakes R., et al. Filamentous alpha-synuclein inclusions link multiple system atrophy with Parkinson's disease and dementia with Lewy bodies. Neurosci Lett 251 (1998) 205-208
4. Wakabayashi K., Yoshimoto M., Tsuji S., and Takahashi H. Alpha-synuclein immunoreactivity in glial cytoplasmic inclusions in multiple system atrophy. Neurosci Lett 249 (1998) 180-182
5. Beyer K., and Ariza A. Protein aggregation mechanisms in synucleinopathies: commonalities and differences. J Neuropathol Exp Neurol 66 (2007) 965-974
6. Gilman S., Low P., Quinn N., et al. Consensus statement on the diagnosis of multiple system atrophy. American Autonomic Society and American Academy of Neurology. Clin Auton Res 8 (1998) 359-362
7. Wenning G.K., Tison F., Seppi K., et al. Development and validation of the unified multiple system atrophy rating scale (UMSARS). Mov Disord 19 (2004) 1391-1402
8. Gilman S., Wenning G.K., Low P.A., et al. Second consensus statement on the diagnosis of multiple system atrophy. Neurology 71 (2008) 670-676
9. Bower J.H., Maraganore D.M., McDonnell S.K., and Rocca W.A. Incidence of progressive supranuclear palsy and multiple system atrophy in Olmsted County, Minnesota, 1976 to 1990. Neurology 49 (1997) 1284-1288
10. Wenning G.K., Colosimo C., Geser F., and Poewe W. Multiple system atrophy. Lancet Neurol 3 (2004) 93-103
11. Wullner U., Schmitz-Hubsch T., Abele M., et al. Features of probable multiple system atrophy patients identified among 4770 patients with parkinsonism enrolled in the multicentre registry of the German Competence Network on Parkinson's disease. J Neural Transm 114 (2007) 1161-1165
12. Schrag A., Wenning G.K., Quinn N., and Shlomo Y.B. Survival in multiple system atrophy. Mov Disord 23 (2008) 294-296
13. Geser F., Wenning G.K., Seppi K., et al. Progression of multiple system atrophy (MSA): a prospective natural history study by the European MSA Study Group (EMSA SG). Mov Disord 21 (2006) 179-186
14. May S., Gilman S., Sowell B.B., et al. Potential outcome measures and trial design issues for multiple system atrophy. Mov Disord 22 (2007) 2371-2377
15. Yabe I., Soma H., Takei A., et al. MSA-C is the predominant clinical phenotype of MSA in Japan: analysis of 142 patients with probable MSA. J Neurol Sci 249 (2006) 115-121
16. Seppi K., Yekhlef F., Diem A., et al. Progression of parkinsonism in multiple system atrophy. J Neurol 252 (2005) 91-96
17. Seppi K., Schocke M.F., Mair K.J., et al. Progression of putaminal degeneration in multiple system atrophy: a serial diffusion MR study. Neuroimage 31 (2006) 240-245
18. Brenneis C., Egger K., Scherfler C., et al. Progression of brain atrophy in multiple system atrophy. A longitudinal VBM study. J Neurol 254 (2007) 191-196
19. Kollensperger M., Stampfer-Kountchev M., Seppi K., et al. Progression of dysautonomia in multiple system atrophy: a prospective study of self-perceived impairment. Eur J Neurol 14 (2007) 66-72
20. Tada M., Onodera O., Tada M., et al. Early development of autonomic dysfunction may predict poor prognosis in patients with multiple system atrophy. Arch Neurol 64 (2007) 256-260
21. O'Sullivan S.S., Massey L.A., Williams D.R., et al. Clinical outcomes of progressive supranuclear palsy and multiple system atrophy. Brain 131 (2008) 1362-1372
22. Geser F., Seppi K., Stampfer-Kountchev M., et al. The European Multiple System Atrophy-Study Group (EMSA-SG). J Neural Transm 112 (2005) 1677-1686
23. Stampfer-Kountchev M., Geser F., Ndayisaba J.P., et al. Evaluation of diagnostic and therapeutic standards for MSA in Europe: first results from the European MSA Registry (EMSA-R). Mov Disord 20 suppl 12 (2005) S144
24. Trojanowski J.Q., and Revesz T. Proposed neuropathological criteria for the post mortem diagnosis of multiple system atrophy. Neuropathol Appl Neurobiol 33 (2007) 615-620
25. Orimo S., Uchihara T., Nakamura A., et al. Axonal alpha-synuclein aggregates herald centripetal degeneration of cardiac sympathetic nerve in Parkinson's disease. Brain 131 (2008) 642-650
26. Mitsui J., Saito Y., Momose T., et al. Pathology of the sympathetic nervous system corresponding to the decreased cardiac uptake in 123I-metaiodobenzylguanidine (MIBG) scintigraphy in a patient with Parkinson disease. J Neurol Sci 243 (2006) 101-104
27. Miyamoto T., Miyamoto M., Suzuki K., et al. 123I-MIBG cardiac scintigraphy provides clues to the underlying neurodegenerative disorder in idiopathic REM sleep behavior disorder. Sleep 31 (2008) 717-723
28. Chung E.J., Lee W.Y., Yoon W.T., Kim B.J., and Lee G.H. MIBG scintigraphy for differentiating Parkinson's disease with autonomic dysfunction from Parkinsonism-predominant multiple system atrophy. Mov Disord 24 (2009) 1650-1655
29. Brooks D.J., and Seppi K. Proposed neuroimaging criteria for the diagnosis of multiple system atrophy. Mov Disord 24 (2009) 949-964
30. Ozawa T., Paviour D., Quinn N.P., et al. The spectrum of pathological involvement of the striatonigral and olivopontocerebellar systems in multiple system atrophy: clinicopathological correlations. Brain 127 (2004) 2657-2671
31. Jellinger K.A., Seppi K., and Wenning G.K. Grading of neuropathology in multiple system atrophy: proposal for a novel scale. Mov Disord 20 suppl 12 (2005) S29-S36
32. Orosz F., Kovacs G.G., Lehotzky A., et al. TPPP/p25: from unfolded protein to misfolding disease: prediction and experiments. Biol Cell 96 (2004) 701-711
33. Song Y.J., Lundvig D.M., Huang Y., et al. p25alpha relocalizes in oligodendroglia from myelin to cytoplasmic inclusions in multiple system atrophy. Am J Pathol 171 (2007) 1291-1303
34. Lindersson E., Lundvig D., Petersen C., et al. p25alpha stimulates alpha-synuclein aggregation and is co-localized with aggregated alpha-synuclein in alpha-synucleinopathies. J Biol Chem 280 (2005) 5703-5715
35. Wenning G.K., Stefanova N., Jellinger K.A., Poewe W., and Schlossmacher M.G. Multiple system atrophy: a primary oligodendrogliopathy. Ann Neurol 64 (2008) 239-246
36. Yoshida M. Multiple system atrophy: alpha-synuclein and neuronal degeneration. Neuropathology 27 (2007) 484-493
37. Trojanowski J.Q., and Revesz T. Proposed neuropathological criteria for the post mortem diagnosis of multiple system atrophy. Neuropathol Appl Neurobiol 33 (2007) 615-620
38. Wakabayashi K., Mori F., Nishie M., et al. An autopsy case of early ("minimal change") olivopontocerebellar atrophy (multiple system atrophy-cerebellar). Acta Neuropathol 110 (2005) 185-190
39. Nishie M., Mori F., Yoshimoto M., Takahashi H., and Wakabayashi K. A quantitative investigation of neuronal cytoplasmic and intranuclear inclusions in the pontine and inferior olivary nuclei in multiple system atrophy. Neuropathol Appl Neurobiol 30 (2004) 546-554
40. Baker K.G., Huang Y., McCann H., Gai W.P., Jensen P.H., and Halliday G.M. p25alpha immunoreactive but alpha-synuclein immunonegative neuronal inclusions in multiple system atrophy. Acta Neuropathol 111 (2006) 193-235
41. Soma H., Yabe I., Takei A., et al. Heredity in multiple system atrophy. J Neurol Sci 240 (2006) 107-110
42. Wullner U., Schmitt I., Kammal M., Kretzschmar H.A., and Neumann M. Definite multiple system atrophy in a German family. J Neurol Neurosurg Psychiatry 80 (2009) 449-450
43. Scholz S.W., Houlden H., Schulte C., et al. SNCA variants are associated with increased risk for multiple system atrophy. Ann Neurol 65 (2009) 610-614
44. Al-Chalabi A., Durr A., Wood N.W., et al. Genetic variants of the alpha-synuclein gene SNCA are associated with multiple system atrophy. PLoS One 4 (2009) e7114
45. Vanacore N. Epidemiological evidence on multiple system atrophy. J Neural Transm 112 (2005) 1605-1612
46. Vidal J.S., Vidailhet M., Elbaz A., et al. Risk factors of multiple system atrophy: a case-control study in French patients. Mov Disord 23 (2008) 797-803
47. Yazawa I., Giasson B.I., Sasaki R., et al. Mouse model of multiple system atrophy alpha-synuclein expression in oligodendrocytes causes glial and neuronal degeneration. Neuron 45 (2005) 847-859
48. Shults C.W., Rockenstein E., Crews L., et al. Neurological and neurodegenerative alterations in a transgenic mouse model expressing human alpha-synuclein under oligodendrocyte promoter: implications for multiple system atrophy. J Neurosci 25 (2005) 10689-10699
49. Stefanova N., Reindl M., Neumann M., et al. Microglial activation mediates neurodegeneration related to oligodendroglial alpha-synucleinopathy: implications for multiple system atrophy. Mov Disord 22 (2007) 2196-3003
50. Stefanova N., Reindl M., Neumann M., et al. Oxidative stress in transgenic mice with oligodendroglial alpha-synuclein overexpression replicates the characteristic neuropathology of multiple system atrophy. Am J Pathol 166 (2005) 869-876
51. Ubhi K., Lee P.H., Adame A., et al. Mitochondrial inhibitor 3-nitroproprionic acid enhances oxidative modification of alpha-synuclein in a transgenic mouse model of multiple system atrophy. J Neurosci Res 87 (2009) 2728-2739
52. Wenning G.K., and Stefanova N. Recent developments in multiple system atrophy. J Neurol 256 (2009) 1791-1808
53. Holmberg B., Johansson J.O., Poewe W., et al. Safety and tolerability of growth hormone therapy in multiple system atrophy: a double-blind, placebo-controlled study. Mov Disord 22 (2007) 1138-1144
54. Bensimon G., Ludolph A., Agid Y., et al. Riluzole treatment, survival and diagnostic criteria in Parkinson plus disorders: the NNIPPS study. Brain 132 (2009) 156-171
55. Olanow C.W., Hauser R.A., Jankovic J., et al. A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): rationale, design, and baseline characteristics. Mov Disord 23 (2008) 2194-2201
56. Poewe W., Hauser R.A., Lang A., and ADAGIO Investigators. Rasagiline 1 mg/day provides benefits in the progression of non-motor symptoms in patients with early Parkinson's disease: assessment with the revised MDS-UPDRAS. Mov Disord 24 (2009) S272-S273
57. Rascol O., and Olanow CWl ADAGIO Investigators. The effect of rasagiline in early Parkinson's disease (PD): the ADAGIO delayed start trial. Mov Disord 24 (2009) S275
58. Stocchi F., and ADAGIO Investigators. Rasagiline provides benefits in the symptoms of fatigue in patients with early Parkinson's disease. Mov Disord 24 (2009) S280-S281
59. Olanow C.W., Rascol O., Hauser R., et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. N Engl J Med 361 (2009) 1268-1278
60. Stefanova N., Poewe W., and Wenning G.K. Rasagiline is neuroprotective in a transgenic model of multiple system atrophy. Exp Neurol 210 (2008) 421-427
61. Li J., Zhu M., Rajamani S., Uversky V.N., and Fink A.L. Rifampicin inhibits alpha-synuclein fibrillation and disaggregates fibrils. Chem Biol 11 (2004) 1513-1521
62. Ubhi K., Rockenstein E., Mante M., et al. Rifampicin reduces alpha-synuclein in a transgenic mouse model of multiple system atrophy. Neuroreport 19 (2008) 1271-1276
63. Stefanova N., Tison F., Reindl M., Poewe W., and Wenning G.K. Animal models of multiple system atrophy. Trends Neurosci 28 (2005) 501-506
64. Stefanova N., Hainzer M., Stemberger S., et al. Striatal transplantation for multiple system atrophy: are grafts affected by alpha-synucleinopathy?. Exp Neurol 219 (2009) 368-371
65. Lee P.H., Kim J.W., Bang O.Y., et al. Autologous mesenchymal stem cell therapy delays the progression of neurological deficits in patients with multiple system atrophy. Clin Pharmacol Ther 83 (2008) 723-730